Pharming Group(ENXTAM) PHARM

Market Cap€703.53M

Since IPO (1999)-99%

5 Year+8%

1 Year-21%

1 Month+13%

€0.99

-0.66%

-0.01Today

Pharming Group last closing stock price
Metric	Price	Date
Last close	EUR 0.99	2026-08-31

Pharming Group stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.12%	EUR 0.99	2026-08-24
1 month	+12.5%	EUR 0.88	2026-07-31
3 month	-8.14%	EUR 1.08	2026-06-02
Year to date	-30.91%	EUR 1.43	2025-12-31
1 year	-20.96%	EUR 1.25	2025-08-29
3 year	-16.27%	EUR 1.18	2023-09-01
5 year	+8.24%	EUR 0.91	2021-09-01
Since inception	-98.94%	EUR 93.80	1999-06-16

Pharming Group Financials at a Glance

Market Cap

€703.53M

Revenue (TTM)

$366.25M

Net Income (TTM)

$9.34M

EPS (TTM)

€0.01

P/E Ratio

87.19

Dividend

€0.00

Beta (Volatility)

0.02 (Low)

Dividend

€0.00

Beta (Volatility)

0.02 (Low)

Price

€0.99

Volume

4,739,419

Open

€0.99

Price

€0.99

Volume

4,739,419

Open

€0.99

Previous Close

€0.99

Daily Range

€0.98 - €0.99

52-Week Range

€0.83 - €1.82

Estimated Earnings Date

Nov 5, 2026

Dividend

€0.00

Beta (Volatility)

0.02 (Low)

Price

€0.99

Volume

4,739,419

Open

€0.99

Previous Close

€0.99

Daily Range

€0.98 - €0.99

52-Week Range

€0.83 - €1.82

Estimated Earnings Date

Nov 5, 2026

PHARM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on developing and marketing protein replacement therapies for rare diseases. The company aims to address critical unmet medical needs through innovative treatments, including its flagship product, Ruconest, which is used for managing hereditary angioedema.

Products and Services

Ruconest: A recombinant human C1 esterase inhibitor for hereditary angioedema
Development pipeline includes rhC1INH for pre-eclampsia and acute kidney injury
Leniolisib: A treatment for activated PI3K delta syndrome

Growth Outlook

Recent quarterly revenue of €88.68 million shows strong market demand
Partnerships with Novartis and Orchard Therapeutics enhance development capabilities
Pipeline expansion targets multiple rare diseases, increasing potential market reach

Financial Highlights

Trailing twelve months (TTM) revenue of €286.5 million reflects solid growth
Current ratio of 3.01 indicates strong liquidity position
Net income of €1.57 million in Q2 2026 demonstrates improving profitability

AI Generated • Aug 3, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Fabrice Chouraqui, MBA

Website

www.pharming.com

Headquarters

Leiden, ZH 2333 CR, NL

PHARM Financials

Key Financial Metrics (TTM)

Gross Margin

86.50%

Operating Margin

3.99%

Net Income Margin

2.55%

Return on Equity

3.50%

Return on Capital

5.31%

Return on Assets

2.00%

Earnings Yield

1.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

€703.53M

Shares Outstanding

707.78M

Volume

4.74M

Avg. Volume

9.68M

Financials (TTM)

Gross Profit

$316.80M

Operating Income

$14.61M

EBITDA

$35.65M

Operating Cash Flow

$31.23M

Capital Expenditure

-$662.01K

Free Cash Flow

$30.56M

Cash & ST Invst.

$158.25M

Total Debt

$126.73M

Pharming Group Performance Analysis

Pharming Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 195,648,930	16.3%
2023	2023-12-31	USD 226,910,054	16.0%
2024	2024-12-31	USD 274,755,052	21.1%
2025	2025-12-31	USD 333,281,365	21.3%

Pharming Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	4.4%
Q4	2025-12-31	10.5%
Q1	2026-03-31	-33.7%
Q2	2026-06-30	26.6%

Pharming Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.02	-4.7%
2023	2023-12-31	USD -0.01	N/A
2024	2024-12-31	USD -0.02	10.1%
2025	2025-12-31	USD 0.00	N/A

Pharming Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	61.4%
Q4	2025-12-31	-38.1%
Q1	2026-03-31	-198.6%
Q2	2026-06-30	127.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$90.21M

-3.2%

Gross Profit

$75.67M

-10.2%

Gross Margin

83.88%

N/A

Market Cap

€703.53M

N/A

Market Cap/Employee

€1.73M

N/A

Employees

407

N/A

Net Income

$1.57M

-66.5%

EBITDA

$4.95M

-49.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$158.25M

+25.6%

Total Debt

$126.73M

-1.2%

Accounts Receivable

$56.97M

+6.8%

Inventory

$65.41M

+2.7%

Long Term Debt

$117.68M

-0.9%

Short Term Debt

$9.05M

-5.4%

Return on Assets

2.00%

N/A

Return on Invested Capital

3.90%

N/A

Free Cash Flow

-$9.74M

-183.9%

Operating Cash Flow

-$9.66M

-182.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About PHARM

What is the current price of Pharming Group?

Pharming Group is trading at €0.99 per share.

What is the 52-week range for Pharming Group?

Over the past 52 weeks, Pharming Group has traded between €0.83 and €1.82.

How much debt does Pharming Group have?

As of the most recent reporting period, Pharming Group reported total debt of $110.87M.

How much cash does Pharming Group have on hand?

Pharming Group reported $138.44M in cash and cash equivalents in its most recent financial results.

What is Pharming Group’s dividend yield?

Pharming Group does not currently have a dividend yield.

Pharming Group(ENXTAM) PHARM

Pharming Group Financials at a Glance

PHARM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Pharming Group

PHARM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Pharming Group Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PHARM

What is the current price of Pharming Group?

What is the 52-week range for Pharming Group?

How much debt does Pharming Group have?

How much cash does Pharming Group have on hand?

What is Pharming Group’s dividend yield?

Premium Investing Services